2-(2-(4-nitrophenoxy)ethoxy)ethanamine | 1613189-26-6

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 2-(2-(4-nitrophenoxy)ethoxy)ethanamine
• 英文别名: 2-[2-(4-Nitrophenoxy)ethoxy]ethanamine；2-[2-(4-nitrophenoxy)ethoxy]ethanamine
• CAS: 1613189-26-6
• 化学式: C₁₀H₁₄N₂O₄
• 分子量: 226.232
• InChiKey: HMTSRXKSDXRECX-UHFFFAOYSA-N

物化性质

• 沸点：
  380.0±27.0 °C(Predicted)
• 密度：
  1.223±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.1
• 重原子数：
  16
• 可旋转键数：
  6
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.4
• 拓扑面积：
  90.3
• 氢给体数：
  1
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  2-(2-(4-nitrophenoxy)ethoxy)ethanamine 在 铁粉 、 potassium carbonate 、 氯化铵 、 N,N-二异丙基乙胺 作用下， 以 乙醇 、 水 、 N,N-二甲基甲酰胺 为溶剂， 反应 34.0h， 生成 4-((2-(2-(4-((3-(4-amino-3-(4-chlorophenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)propyl)amino)phenoxy)ethoxy)ethyl)amino)-2-(2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione
  参考文献：
  名称：

  Design, Synthesis, and Biological Evaluation of Proteolysis Targeting Chimeras (PROTACs) for the Dual Degradation of IGF-1R and Src

  摘要：

  开发了一个专注于降解与各种癌症相关的IGF-1R和Src蛋白的PROTAC文库。通过将不同的抑制剂战斗单元和E3连接酶（CRBN）招募-泼美度胺与不同的连接剂相结合，合成了具有IGF-1R和Src降解潜力的PROTAC。设计的PROTACs 12a-b在各种细胞实验中以低微摩尔效力（1-5μM）抑制了MCF7和A549癌细胞的增殖和迁移。

  DOI：

  10.3390/molecules25081948
• 作为产物：
  描述：

  1-(2-(2-azidoethoxy)ethoxy)-4-nitrobenzene 在 三苯基膦 作用下， 以 四氢呋喃 、 水 为溶剂， 以85.08%的产率得到2-(2-(4-nitrophenoxy)ethoxy)ethanamine
  参考文献：
  名称：

  Design, Synthesis, and Biological Evaluation of Proteolysis Targeting Chimeras (PROTACs) for the Dual Degradation of IGF-1R and Src

  摘要：

  开发了一个专注于降解与各种癌症相关的IGF-1R和Src蛋白的PROTAC文库。通过将不同的抑制剂战斗单元和E3连接酶（CRBN）招募-泼美度胺与不同的连接剂相结合，合成了具有IGF-1R和Src降解潜力的PROTAC。设计的PROTACs 12a-b在各种细胞实验中以低微摩尔效力（1-5μM）抑制了MCF7和A549癌细胞的增殖和迁移。

  DOI：

  10.3390/molecules25081948

文献信息

• Discovery of TD-4306, a long-acting β2-agonist for the treatment of asthma and COPD
  作者：R. Murray McKinnell、Uwe Klein、Martin S. Linsell、Edmund J. Moran、Matthew B. Nodwell、Juergen W. Pfeiffer、G. Roger Thomas、Cecile Yu、John R. Jacobsen

  DOI：10.1016/j.bmcl.2014.04.095

  日期：2014.7

  A multivalent approach focused on amine-based secondary binding groups was applied to the discovery of long-acting inhaled beta(2)-agonists. Addition of amine moieties to the neutral secondary binding group of an existing beta(2)-agonist series was found to provide improved in vivo efficacy, but also led to the formation of biologically active aldehyde metabolites which were viewed as a risk for the development of these compounds. Structural simplification of the scaffold and blocking the site of metabolism to prevent aldehyde formation afforded a potent series of dibasic beta(2)-agonists with improved duration of action relative to their monobasic analogs. Additional optimization led to the discovery of 29 (TD-4306), a potent and selective beta(2)-agonist with potential for once-daily dosing. (C) 2014 Elsevier Ltd. All rights reserved.
• Design, Synthesis, and Biological Evaluation of Proteolysis Targeting Chimeras (PROTACs) for the Dual Degradation of IGF-1R and Src
  作者：Sudhakar Manda、Na Keum Lee、Dong-Chan Oh、Jeeyeon Lee

  DOI：10.3390/molecules25081948

  日期：——

  A focused PROTAC library was developed to degrade both IGF-1R and Src proteins, which are associated with various cancers. PROTACs with IGF-1R and Src degradation potentials were synthesized by tethering different inhibitor warhead units and the E3 ligase (CRBN) recruiting-pomalidomide with various linkers. The designed PROTACs 12a–b inhibited the proliferation and migration of MCF7 and A549 cancer cells with low micromolar potency (1–5 μM) in various cellular assays.

  开发了一个专注于降解与各种癌症相关的IGF-1R和Src蛋白的PROTAC文库。通过将不同的抑制剂战斗单元和E3连接酶（CRBN）招募-泼美度胺与不同的连接剂相结合，合成了具有IGF-1R和Src降解潜力的PROTAC。设计的PROTACs 12a-b在各种细胞实验中以低微摩尔效力（1-5μM）抑制了MCF7和A549癌细胞的增殖和迁移。